Thyroid Cancer Management

Introduction to Thyroid Cancer Management

Thyroid cancer management involves various strategies, including TSH suppression therapy, to replace thyroid hormone and suppress the potential growth stimulus of TSH on tumor cells, as noted by Annals of Oncology 1

For patients with thyroid cancer on levothyroxine replacement therapy, the National Comprehensive Cancer Network recommends maintaining TSH levels below 0.1 mU/L for those with known residual carcinoma or at high risk for recurrence, and slightly below or slightly above the lower limit of the reference range for disease-free patients at low risk for recurrence 2, 1
Patients with persistent or metastatic disease should have TSH levels maintained below 0.1 mU/L, as recommended by the National Comprehensive Cancer Network and supported by Annals of Oncology 2, 1

TSH suppressive treatment with levothyroxine has been shown to decrease progression of metastatic disease in high-risk thyroid cancer patients, thus reducing cancer-related mortality, as stated by the National Comprehensive Cancer Network 1
The goal of TSH suppression therapy is to replace thyroid hormone and suppress the potential growth stimulus of TSH on tumor cells, as noted by Annals of Oncology 1

Long-term TSH suppression therapy carries potential risks, including cardiac tachyarrhythmias, bone demineralization, and symptoms of thyrotoxicosis, as reported by the National Comprehensive Cancer Network 2
Patients on TSH-suppressive therapy should ensure adequate daily intake of calcium (1200 mg/d) and vitamin D (1000 units/d) to mitigate the risk of bone demineralization, as recommended by the National Comprehensive Cancer Network 2
Biotin supplements can interfere with assay results, causing either under or overestimation, according to the Endocrine Society 3

TSH testing can diagnose thyroid disease with high sensitivity (98%) and specificity (92%), and values below 0.1 mU/L are considered low, while values above 6.5 mU/L are considered elevated, as recommended by the American College of Physicians 4, 5
The following table summarizes the diagnosis of different thyroid conditions:

Condition	TSH	Free T4	Diagnosis
Subclinical Hypothyroidism	Elevated	Normal	Mild hypothyroidism
Overt Hypothyroidism	Elevated	Low	Severe hypothyroidism
Subclinical Hyperthyroidism	Low	Normal	Mild hyperthyroidism
Overt Hyperthyroidism	Low	Elevated	Severe hyperthyroidism

Thyroid function tests (TSH, free T4) should be monitored every 6-12 months for stable patients, and every 3-6 months for patients with recent dose adjustments, as per the Annals of Oncology guidelines 7

Screening is recommended for women over 50 years with general symptoms, postpartum women, pregnant women, and women planning pregnancy, as well as patients with Down syndrome and individuals with high levels of radiation exposure (>20 mGy), with varying strengths of evidence 4, 5
Oral levothyroxine monotherapy is the standard treatment for hypothyroidism, with a high strength of evidence, and treatment is generally recommended when TSH exceeds 10 mIU/L, as recommended by the American College of Endocrinology 8, 6
Patients with symptoms compatible with hypothyroidism should be considered for treatment with levothyroxine, with a moderate strength of evidence 9

Untreated hypothyroidism can lead to serious complications, including cardiovascular disease and increased mortality, with high strength of evidence 6
Untreated subclinical hypothyroidism may progress to overt hypothyroidism at a rate of 2.6-4.3% per year, with moderate strength of evidence 9
Thyroid hormone replacement therapy can lead to potential long-term complications, including cardiovascular effects, bone mineral density loss, and risk of overtreatment, with a moderate strength of evidence 6, 10